(triazolam)
Table 2 includes clinically significant drug interactions with Halcion [see Clinical Pharmacology (12.3)].
Opioids | |
Clinical implication | The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. |
Prevention or management | Limit dosage and duration of concomitant use of Halcion and opioids, and monitor patients closely for respiratory depression and sedation [see Warnings and Precautions (5.1)]. |
CNS Depressants | |
Clinical implication | Triazolam produces additive CNS depressant effects when co-administered with other CNS depressants. |
Prevention or management | Limit dosage and duration of Halcion during concomitant use with CNS depressants. |
Strong Inhibitors of CYP 3A | |
Clinical implication | Concomitant use of Halcion with strong CYP3A inhibitors has a profound effect on the clearance of Halcion, resulting in increased concentrations of triazolam and increased risk of adverse reactions [see Clinical Pharmacology (12.3)]. |
Prevention or management | Do not administer Halcion with a strong CYP3A4 inhibitor [see Contraindications (4), Warnings and Precautions (5.8)]. |
Moderate and Weak Inhibitors of CYP 3A | |
Clinical implication | Concomitant use of Halcion with moderate or weak inhibitors of CYP3A inhibitors may increase the concentrations of Halcion, resulting in increased risk of adverse reactions [see Clinical Pharmacology (12.3)]. |
Prevention or management | Use with caution and consider appropriate dose reduction of HALCION when coadministered with moderate and weak CYP3A inhibitors [see Warnings and Precautions (5.8)]. |
Strong Inducers of CYP 3A | |
Clinical implication | Coadministration of triazolam with strong inducers of CYP3A4 can significantly decrease the plasma concentration of triazolam and may decrease effectiveness of triazolam. |
Prevention or management | Caution is recommended during coadministration of Halcion with strong inducers of CYP3A4. |
Interactions Based on Experience with Other Benzodiazepines or in vitro Studies with Triazolam | |
Clinical implication | Available data from clinical studies of benzodiazepines other than triazolam, from in vitro studies with triazolam, or from in vitro studies with benzodiazepines other than triazolam suggest a possible drug interaction with triazolam [see Clinical Pharmacology (12.3)]. |
Prevention or management | Caution is recommended during coadministration of Halcion with any of these drugs. [see Warnings and Precautions (5.8)]. |
| MEDICATION GUIDE HALCION (HAL-cee-on) (triazolam) tablets, CIV | ||
|---|---|---|
| This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised 7/2024 | ||
What is the most important information I should know about HALCION?
| ||
|
| |
Call your healthcare provider right away if you find out that you have done any of the above activities after taking HALCION. | ||
What is HALCION? HALCION is a prescription medicine used in adults for the short-term treatment of a sleep problem called insomnia. HALCION is usually taken for 7 to 10 days.
| ||
Do not take HALCION if you:
| ||
Before you take HALCION, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking HALCION with certain other medicines can cause side effects or affect how well HALCION or the other medicines work. Do not start or stop other medicines without talking to your healthcare provider. | ||
How should I take HALCION?
| ||
What are the possible side effects of HALCION? HALCION may cause serious side effects, including:
| ||
The most common side effects of HALCION include: | ||
|
| |
Elderly people have an increased risk of dose related side effects during treatment with HALCION. These are not all the possible side effects of HALCION. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | ||
How should I store HALCION?
| ||
General information about the safe and effective use of HALCION. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use HALCION for a condition for which it was not prescribed. Do not give HALCION to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about HALCION that is written for healthcare professionals. | ||
What are the ingredients in HALCION? Active ingredient: triazolam Inactive ingredients: cellulose, corn starch, docusate sodium, FD&C Blue No. 2, lactose, magnesium stearate, silicon dioxide, sodium benzoate. ![]() If you would like more information, call 1-800-438-1985 or visit www.pfizer.com. LAB-0259-19.0 | ||
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.